565 related articles for article (PubMed ID: 25941226)
41. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.
Gupta S; Cohen KA; Winglee K; Maiga M; Diarra B; Bishai WR
Antimicrob Agents Chemother; 2014; 58(1):574-6. PubMed ID: 24126586
[TBL] [Abstract][Full Text] [Related]
42. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
43. Whole-genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis.
Chawla K; Martinez E; Kumar A; Shenoy VP; Sintchenko V
J Glob Antimicrob Resist; 2018 Dec; 15():103-104. PubMed ID: 30248414
[TBL] [Abstract][Full Text] [Related]
44. Tuberculosis: clinical trials and new drug regimens.
Kwon YS; Jeong BH; Koh WJ
Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
[TBL] [Abstract][Full Text] [Related]
45. Sub-MIC levels of bedaquiline and clofazimine can select
Villellas C; Stevenaert F; Remmerie B; Andries K
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
[TBL] [Abstract][Full Text] [Related]
46. Bedaquiline.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
[No Abstract] [Full Text] [Related]
47. A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.
Kaniga K; Cirillo DM; Hoffner S; Ismail NA; Kaur D; Lounis N; Metchock B; Pfyffer GE; Venter A
J Clin Microbiol; 2016 Dec; 54(12):2956-2962. PubMed ID: 27654337
[TBL] [Abstract][Full Text] [Related]
48. Bedaquiline (Sirturo) for multidrug-resistant tuberculosis.
Med Lett Drugs Ther; 2013 Aug; 55(1423):66-8. PubMed ID: 23959388
[No Abstract] [Full Text] [Related]
49. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
[TBL] [Abstract][Full Text] [Related]
50. Genetics and roadblocks of drug resistant tuberculosis.
Perdigão J; Portugal I
Infect Genet Evol; 2019 Aug; 72():113-130. PubMed ID: 30261266
[TBL] [Abstract][Full Text] [Related]
51. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.
Kobayashi M; Motoki Y; Yamagishi T; Hirano H; Nonaka M; Aono A; Mitarai S; Saito T
J Infect Chemother; 2022 Aug; 28(8):1193-1197. PubMed ID: 35550867
[TBL] [Abstract][Full Text] [Related]
52. Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus.
Li B; Ye M; Guo Q; Zhang Z; Yang S; Ma W; Yu F; Chu H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712658
[TBL] [Abstract][Full Text] [Related]
53. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
Martinez E; Hennessy D; Jelfs P; Crighton T; Chen SC; Sintchenko V
Tuberculosis (Edinb); 2018 Jul; 111():31-34. PubMed ID: 30029911
[TBL] [Abstract][Full Text] [Related]
54. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
55. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
Diacon AH; Pym A; Grobusch MP; de los Rios JM; Gotuzzo E; Vasilyeva I; Leimane V; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; De Paepe E; van Heeswijk RP; Dannemann B;
N Engl J Med; 2014 Aug; 371(8):723-32. PubMed ID: 25140958
[TBL] [Abstract][Full Text] [Related]
56. Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.
Peretokina IV; Krylova LY; Antonova OV; Kholina MS; Kulagina EV; Nosova EY; Safonova SG; Borisov SE; Zimenkov DV
J Infect; 2020 May; 80(5):527-535. PubMed ID: 31981638
[TBL] [Abstract][Full Text] [Related]
57. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Li Y; Sun F; Zhang W
Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
[TBL] [Abstract][Full Text] [Related]
58. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Blair HA; Scott LJ
Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
[TBL] [Abstract][Full Text] [Related]
59. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
60. Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid.
Van den Bossche A; Varet H; Sury A; Sismeiro O; Legendre R; Coppee JY; Mathys V; Ceyssens PJ
Tuberculosis (Edinb); 2019 Jul; 117():18-23. PubMed ID: 31378263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
